XGN vs CDNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jul 25, 2026

XGN

59.7
AI Score
VS
XGN Wins

CDNA

48.0
AI Score

Investment Advisor Scores

XGN

60score
Recommendation
HOLD

CDNA

48score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric XGN CDNA Winner
Revenue 17.31M 117.70M CDNA
Net Income -3.97M 2.81M CDNA
Net Margin -22.9% 2.4% CDNA
Operating Income -3.41M 1.20M CDNA
ROE -27.5% 0.9% CDNA
ROA -7.6% 0.7% CDNA
Total Assets 51.96M 411.06M CDNA
Cash 21.51M 77.92M CDNA
Current Ratio 3.47 3.40 XGN
Free Cash Flow -10.64M 514,000 CDNA

Relative Price Performance (Last 90 Days)

XGN 1M: -3.8% · 3M: +56.2% CDNA 1M: +49.4% · 3M: +110.0%

Current Technical Phase

XGN

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 51

RSI (14): 50.5 · Price: $4.53

CDNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (23.4% over 20 days), RSI 77

RSI (14): 77.4 · Price: $43.71

Fundamentals Snapshot

Metric XGN CDNA
Market Cap
Forward P/E -10.5 38.5
Trailing P/E
Revenue (TTM)
Revenue Growth 0.1% 0.4%
Gross Margin 0.6% 0.7%
Operating Margin -0.2% 0.0%
EPS -0.97 -0.17
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, XGN is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.